Aurora Cannabis Inc. (TSX:ACB), one of the Canadian marijuana stocks, said recently it has partnered with mixed martial arts company UFC for CBD research
SmallCapPower | May 29, 2019: Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB), one of the Canadian cannabis stocks, announced recently that it has entered into an exclusive, multi-year, multi-million dollar, global partnership with UFC, the world’s premier mixed martial arts organization, to advance Cannabidiol (CBD) research. The partnership is expected to establish a relationship between hemp-derived CBD products and athlete wellness and recovery.
Headquartered in Las Vegas, UFC boasts more than 300 million fans worldwide, including 70 million social media followers across all of its digital platforms, and its programming is broadcast in over 170 countries and territories to one billion TV households worldwide in 40 different languages.
The research will be conducted at the UFC’s Performance Institute, the world’s first mixed martial arts multi-disciplinary research, innovation, and training center in Las Vegas, where more than 400 athletes over the past two years have been served. This research will be focusing on pain management, inflammation, injury/exercise recovery, and mental well-being. Aurora’s research will be led by Dr. Jason Dyck, a professor at the University of Alberta and a Canada Research Chair in molecular medicine. He also serves as an independent director on the board of Aurora Cannabis.
Aurora Cannabis CEO Terry Booth said, “This global partnership places focus squarely on the health and well-being of UFC’s talented and highly trained athletes. The Aurora-UFC research partnership creates a global platform to launch targeted educational and awareness campaigns, while creating numerous opportunities to accelerate our global CBD business.”
Headquartered in Edmonton, Aurora Cannabis is one of the largest and leading vertically-integrated cannabis companies, having annual funded capacity of 625,000 kg and sales and operations in 24 countries across five continents. Aurora has a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities, which generates massive scale production of high-quality consistent product. All of Aurora’s facilities are designed and built to the EU GMP standard.
Aurora Cannabis stock currently trades at a market capitalization of C$11.5 billion with a price-to-book multiple of 2.4x.
Disclosure: Neither the author nor his family own shares in the company mentioned above.
To read our full disclosure, please click on the button below: